Physician profile
Valerie F Kolbert
NPI 1902994510
$14,741.41
in general payments reported to CMS, 2019-2025
22 companies · $3,367 in 2025
The $3,367 reported for 2025 was more than what 97% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,633 · 2022: $2,144 · 2023: $3,637 · 2024: $3,960 · 2025: $3,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,964.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,595.18 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $2,456.93 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,702.75 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,673.05 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,285.21 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,018.57 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,000.72 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $878.26 | 2022-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $592.80 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $241.46 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $241.07 | 2021-2022 | |
| Lundbeck LLC | $198.62 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $188.72 | 2025 | Qelbree |
| Bausch Health US, LLC | $145.14 | 2022-2024 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $141.61 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $122.50 | 2024 | Xelstrym |
| Livanova USA, INC. | $112.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.27 | 2021-2022 | |
| Harmony Biosciences LLC | $43.74 | 2025 | |
| Acadia Pharmaceuticals INC | $24.66 | 2022 | |
| Alfasigma USA, INC. | $20.11 | 2021 | |
| Eisai INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valerie Kolbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.